Oxybutynin chlorideCAS# 1508-65-2 |
- Daptomycin
Catalog No.:BCC1057
CAS No.:103060-53-3
- Nelarabine
Catalog No.:BCC1072
CAS No.:121032-29-9
- Gemcitabine HCl
Catalog No.:BCC1076
CAS No.:122111-03-9
- Clofarabine
Catalog No.:BCC1078
CAS No.:123318-82-1
- Ifosfamide
Catalog No.:BCC1164
CAS No.:3778-73-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1508-65-2 | SDF | Download SDF |
| PubChem ID | 91505 | Appearance | Powder |
| Formula | C22H32ClNO3 | M.Wt | 393.95 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (253.84 mM) H2O : 33.33 mg/mL (84.60 mM; Need ultrasonic) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate;hydrochloride | ||
| SMILES | CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O.Cl | ||
| Standard InChIKey | SWIJYDAEGSIQPZ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H31NO3.ClH/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20;/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3;1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties.
Target: mAChR
Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination (urge incontinence), by decreasing muscle spasms of the bladder. Oxybutynin competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor. It also has direct spasmolytic effects on bladder smooth muscle as a calcium antagonist and local anesthetic, but at concentrations far above those used clinically. Oxybutynin is available orally in generic formulation or as the brand-names Ditropan, Lyrinel XL, or Ditrospam, as a transdermal patch under the brand name Oxytrol, and as a topical gel under the brand name Gelnique. Oxybutynin is also a possible treatment of hyperhidrosis (hyper-active sweating) [1-3]. References: | |||||
Oxybutynin chloride Dilution Calculator
Oxybutynin chloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.5384 mL | 12.692 mL | 25.3839 mL | 50.7679 mL | 63.4598 mL |
| 5 mM | 0.5077 mL | 2.5384 mL | 5.0768 mL | 10.1536 mL | 12.692 mL |
| 10 mM | 0.2538 mL | 1.2692 mL | 2.5384 mL | 5.0768 mL | 6.346 mL |
| 50 mM | 0.0508 mL | 0.2538 mL | 0.5077 mL | 1.0154 mL | 1.2692 mL |
| 100 mM | 0.0254 mL | 0.1269 mL | 0.2538 mL | 0.5077 mL | 0.6346 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Oxybutynin is an anticholinergic medication used to relieve urinary and bladder difficulties.
- Gap19
Catalog No.:BCC5599
CAS No.:1507930-57-5
- Drynachromoside A
Catalog No.:BCN7891
CAS No.:1507388-29-5
- Calyxamine B
Catalog No.:BCN1671
CAS No.:150710-72-8
- 5-Methoxycanthin-6-one
Catalog No.:BCN3326
CAS No.:15071-56-4
- Tolvaptan
Catalog No.:BCC5096
CAS No.:150683-30-0
- Fmoc-Lys(Dde)-OH
Catalog No.:BCC3518
CAS No.:150629-67-7
- epi-Eudesmol
Catalog No.:BCN1670
CAS No.:15051-81-7
- L-NIL hydrochloride
Catalog No.:BCC5706
CAS No.:150403-89-7
- o-Methoxycinnamaldehyde
Catalog No.:BCN3860
CAS No.:1504-74-1
- Pemetrexed disodium
Catalog No.:BCN2179
CAS No.:150399-23-8
- MRS 2690
Catalog No.:BCC7514
CAS No.:15039-58-4
- SR 49059
Catalog No.:BCC7324
CAS No.:150375-75-0
- Tropicamide
Catalog No.:BCC4574
CAS No.:1508-75-4
- Retigabine
Catalog No.:BCC6427
CAS No.:150812-12-7
- Retigabine dihydrochloride
Catalog No.:BCC1890
CAS No.:150812-13-8
- 2,3,24-Trihydroxyolean-12-en-28-oic acid
Catalog No.:BCN1559
CAS No.:150821-16-2
- Nitenpyram
Catalog No.:BCC5559
CAS No.:150824-47-8
- EGF816
Catalog No.:BCC6428
CAS No.:1508250-71-2
- Boc-Orn(Fmoc)-OH
Catalog No.:BCC3429
CAS No.:150828-96-9
- Micromelin
Catalog No.:BCN1672
CAS No.:15085-71-9
- Uralenol-3-methylether
Catalog No.:BCN7993
CAS No.:150853-98-8
- Bis(phenylacetyl) disulfide
Catalog No.:BCC8887
CAS No.:15088-78-5
- Euonymine
Catalog No.:BCN3084
CAS No.:150881-01-9
- Aurantiamide benzoate
Catalog No.:BCN8043
CAS No.:150881-02-0
Efficacy, tolerability, and safety of oxybutynin chloride in pediatric neurogenic bladder with spinal dysraphism: a retrospective, multicenter, observational study.[Pubmed:25512818]
Korean J Urol. 2014 Dec;55(12):828-33.
PURPOSE: Anticholinergics are a key element in treating neurogenic detrusor overactivity, but only limited data are available in the pediatric population, thus limiting the application to children even for Oxybutynin chloride (OC), a prototype drug. This retrospective study was designed to provide data regarding the efficacy, tolerability, and safety of OC in the pediatric population (0-15 years old) with spinal dysraphism (SD). MATERIALS AND METHODS: Records relevant to OC use for neurogenic bladder were gathered and scrutinized from four specialized clinics for pediatric urology. The primary efficacy outcomes were maximal cystometric capacity (MCC) and end filling pressure (EFP). Data on tolerability, compliance, and adverse events (AEs) were also analyzed. RESULTS: Of the 121 patient records analyzed, 41 patients (34%) received OC at less than 5 years of age. The range of prescribed doses varied from 3 to 24 mg/d. The median treatment duration was 19 months (range, 0.3-111 months). Significant improvement of both primary efficacy outcomes was noted following OC treatment. MCC increased about 8% even after adjustment for age-related increases in MCC. Likewise, mean EFP was reduced from 33 to 21 cm H2O. More than 80% of patients showed compliance above 70%, and approximately 50% of patients used OC for more than 1 year. No serious AEs were reported; constipation and facial flushing consisted of the major AEs. CONCLUSIONS: OC is safe and efficacious in treating pediatric neurogenic bladder associated with SD. The drug is also tolerable and the safety profile suggests that adjustment of dosage for age may not be strictly observed.
Transdermal delivery of oxybutynin chloride proniosomal gels for the treatment of overactive bladder.[Pubmed:26634274]
Drug Deliv. 2016 Jun;23(5):1578-87.
CONTEXT: Overactive bladder (OAB) is a common problem and anticholinergic drugs are first-line therapy, but they have side effects. OBJECTIVE: Development of Oxybutynin chloride (OC) proniosomal gels and analyses of its efficacy for OAB treatment. MATERIALS AND METHODS: Phase separation coacervation was used to prepare proniosomal gels using various non-ionic surfactants, lipids, soy lecithin and isopropyl alcohol. Gels were characterized with regard to entrapment efficiency (EE), vesicle size, surface morphology (using environmental scanning electron microscopy [E-SEM]), stability, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, in vitro skin permeation, in vivo animal studies and histopathology. RESULTS AND DISCUSSION: EE was 87-92%, vesicle size was 0.38-5.0 mum, and morphology showed some loosened pores in proniosomes after hydration. ATR-FTIR spectroscopy showed no significant shifts in peaks corresponding to OC and excipients. Most formulations exhibited >50% permeation but the cholesterol-containing formulations P3 (Span 20:Span 60 [1:1]) and P4 [Tween 20:Tween 80 (1:1)] had the highest percent cumulative permeation. P3 and P4 also showed faster recovery of cholinergic effects on salivary glands than oral formulations. P3 and P4 had pronounced therapeutic effects in reduction of urinary frequency and demonstrated improvements in bladder morphology (highly regenerative surface of the transitional epithelium). CONCLUSION: These results suggest that OC could be incorporated into proniosomal gels for transdermal delivery in the treatment of OAB.
Treatment outcomes according to neuropathic bladder sphincter dysfunction type after treatment of oxybutynin chloride in children with myelodysplasia.[Pubmed:23543139]
Int Urol Nephrol. 2013 Jun;45(3):703-9.
PURPOSE: We investigated the treatment outcomes according to neuropathic bladder sphincter dysfunction (NBSD) type after oral oxybutynin (OBT) treatment in children with NBSD caused by myelodysplasia. METHODS: Among 334 pediatric patients who were diagnosed with NBSD caused by myelodysplasia, only children treated with oral OBT for more than 1 year with pre- and post-treatment urodynamic studies and dimercaptosuccinic acid (DMSA) were retrospectively reviewed. We compared pre- and post-treatment urodynamic parameters including maximum cystometric capacity (MCC), MCC/estimated bladder capacity (EBC), and compliance by NBSD type in children. We also compared renal scarring on pre- and post-treatment DMSA by NBSD type in children. RESULTS: Our study population was comprised of 81 children (45 boys and 36 girls), with a mean age of 4.2 +/- 3.4 years. The mean follow-up duration was 4.5 (range 1.0-15.1) years. After OBT treatment, MCC was increased significantly in all types of NBSD from 110.3 +/- 62.2 to 202.3 +/- 103.9 ml (p < 0.05), compliance was significantly improved from 6.4 +/- 6.1 to 11.1 +/- 9.6 ml/cmH2O (p < 0.05), but MCC/EBC was slightly decreased from 75.2 +/- 46.9 to 69.8 +/- 33.3 % (p = 0.40). Sub-analyzed by NBSD type, the pre-treatment compliance of children with acontractile detrusor with spastic sphincter (n = 16) was markedly decreased compared with other types of NBSD. Acontractile detrusor with spastic sphincter demonstrated the worst renal deterioration on DMSA. CONCLUSIONS: Although increases in MCC/EBC were limited, oral OBT treatment markedly improved MCC and compliance in all NBSD types. Children who had acontractile detrusor with spastic sphincter had a relatively high probability of renal deterioration and required specific attention.
